Taarika Babu
YOU?
Author Swipe
View article: Novel MgFe2O4/TiO2/ZnO Nanocomposites Synthesized by Sol-Gel Method for Visible Light Photocatalytic Degradation of Eosin Y Dye
Novel MgFe2O4/TiO2/ZnO Nanocomposites Synthesized by Sol-Gel Method for Visible Light Photocatalytic Degradation of Eosin Y Dye Open
The synthesized magnesium ferrite-titania-zinc oxide nanocomposites are extremely successful in the photocatalytic degradation of eosin Y dye because of their size, stability, structure, eco-friendliness and high efficiency. The UV-visible…
View article: Supplementary Tables from Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer
Supplementary Tables from Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer Open
Supplementary Table 1: Nanoparticle physicochemical characteristics. Table S2: IC50 values of various formulations against various bladder cancer cell lines.
View article: Data from Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer
Data from Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer Open
Purpose: Prior clinical trials evaluating cisplatin for non–muscle-invasive bladder cancer (NMIBC) were stopped due to local and systemic toxicity. Currently, there is still a need for improved intravesical therapies, and nanopartic…
View article: Figures S1-S4 from Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer
Figures S1-S4 from Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer Open
Supplementary Figure 1: Transmission electron micrographs of PAA-CDDP NPs, PEGlow-PAA-CDDP NPs and PEGhigh-PAA-CDDP NPs (Scale bars = 500 nm). Supplementary Figure 2. Apoptosis was compared in RT4 cells treated with CDDP and PAA-CDDP NPs. …
View article: Supplementary Tables from Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer
Supplementary Tables from Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer Open
Supplementary Table 1: Nanoparticle physicochemical characteristics. Table S2: IC50 values of various formulations against various bladder cancer cell lines.
View article: Data from Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer
Data from Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer Open
Purpose: Prior clinical trials evaluating cisplatin for non–muscle-invasive bladder cancer (NMIBC) were stopped due to local and systemic toxicity. Currently, there is still a need for improved intravesical therapies, and nanopartic…
View article: Figures S1-S4 from Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer
Figures S1-S4 from Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer Open
Supplementary Figure 1: Transmission electron micrographs of PAA-CDDP NPs, PEGlow-PAA-CDDP NPs and PEGhigh-PAA-CDDP NPs (Scale bars = 500 nm). Supplementary Figure 2. Apoptosis was compared in RT4 cells treated with CDDP and PAA-CDDP NPs. …